LENZ THERAPEUTICS INC (LENZ) Stock Price, Quote, News and Overview
NASDAQ:LENZ - Nasdaq - US52635N1037 - Common Stock - Currency: USD
LENZ Quote, Performance and Key Statistics
31.62
-1.78 (-5.33%)
The current stock price of LENZ is 31.62 USD. In the past month the price increased by 5.01%. In the past year, price increased by 31.91%.
LENZ Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 59.06 | 770.22B | ||
| JNJ | JOHNSON & JOHNSON | 16.83 | 404.94B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 19.38 | 318.59B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.3 | 227.85B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.7 | 225.28B | ||
| MRK | MERCK & CO. INC. | 10.87 | 212.71B | ||
| PFE | PFIZER INC | 7.72 | 140.94B | ||
| SNY | SANOFI-ADR | 11 | 122.61B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.6 | 98.56B | ||
| GSK | GSK PLC-SPON ADR | 8.49 | 76.70B | ||
| ZTS | ZOETIS INC | 25.27 | 67.73B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 60.33 | 45.73B |
Related stock screener links
About LENZ
Company Profile
LENZ Therapeutics, Inc. operates as a clinical stage company, which develops ophthalmic pharmaceutical products. The company is headquartered in Solana Beach, California and currently employs 42 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
Company Info
LENZ THERAPEUTICS INC
201 Lomas Santa Fe Drive, Suite 300
Solana Beach CALIFORNIA US
Employees: 42
Phone: 18589257000
LENZ THERAPEUTICS INC / LENZ FAQ
What is the stock price of LENZ THERAPEUTICS INC today?
The current stock price of LENZ is 31.62 USD. The price decreased by -5.33% in the last trading session.
What is the ticker symbol for LENZ THERAPEUTICS INC stock?
The exchange symbol of LENZ THERAPEUTICS INC is LENZ and it is listed on the Nasdaq exchange.
On which exchange is LENZ stock listed?
LENZ stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for LENZ THERAPEUTICS INC stock?
14 analysts have analysed LENZ and the average price target is 45.03 USD. This implies a price increase of 42.4% is expected in the next year compared to the current price of 31.62. Check the LENZ THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is LENZ THERAPEUTICS INC worth?
LENZ THERAPEUTICS INC (LENZ) has a market capitalization of 890.10M USD. This makes LENZ a Small Cap stock.
How many employees does LENZ THERAPEUTICS INC have?
LENZ THERAPEUTICS INC (LENZ) currently has 42 employees.
What are the support and resistance levels for LENZ THERAPEUTICS INC (LENZ) stock?
LENZ THERAPEUTICS INC (LENZ) has a support level at 31.61 and a resistance level at 34.7. Check the full technical report for a detailed analysis of LENZ support and resistance levels.
Should I buy LENZ THERAPEUTICS INC (LENZ) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LENZ, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LENZ, evaluating the profitability, health, valuation and growth aspects
- LENZ THERAPEUTICS INC (LENZ) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LENZ THERAPEUTICS INC (LENZ) Sales and EPS estimates to see what analysts future expectations are.
- LENZ THERAPEUTICS INC (LENZ) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LENZ THERAPEUTICS INC (LENZ) Insider and Institutional Ownership to learn about the owners and their transactions.
- LENZ THERAPEUTICS INC (LENZ) Stock Chart to make your own analysis
- LENZ THERAPEUTICS INC (LENZ) Latest news and press-releases to stay up to date.
Does LENZ THERAPEUTICS INC (LENZ) stock pay dividends?
LENZ does not pay a dividend.
When does LENZ THERAPEUTICS INC (LENZ) report earnings?
LENZ THERAPEUTICS INC (LENZ) will report earnings on 2025-08-13, after the market close.
What is the Price/Earnings (PE) ratio of LENZ THERAPEUTICS INC (LENZ)?
LENZ THERAPEUTICS INC (LENZ) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.77).
What is the Short Interest ratio of LENZ THERAPEUTICS INC (LENZ) stock?
The outstanding short interest for LENZ THERAPEUTICS INC (LENZ) is 13.4% of its float. Check the ownership tab for more information on the LENZ short interest.
LENZ Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to LENZ. When comparing the yearly performance of all stocks, LENZ is one of the better performing stocks in the market, outperforming 82.57% of all stocks.
LENZ Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LENZ. No worries on liquidiy or solvency for LENZ as it has an excellent financial health rating, but there are worries on the profitability.
LENZ Financial Highlights
Over the last trailing twelve months LENZ reported a non-GAAP Earnings per Share(EPS) of -1.77. The EPS increased by 88.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.72% | ||
| ROE | -24.86% | ||
| Debt/Equity | 0 |
LENZ Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to LENZ. The Buy consensus is the average rating of analysts ratings from 14 analysts.